We're building a better ClinicalTrials.gov. Check it out and tell us what you think!
Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 2 of 3 for:    LYR-210

Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis in Adults (ENLIGHTEN 1)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT05219968
Recruitment Status : Recruiting
First Posted : February 2, 2022
Last Update Posted : October 26, 2022
Sponsor:
Information provided by (Responsible Party):
Lyra Therapeutics

Brief Summary:
Multicenter, phase III, randomized, blinded, controlled, parallel group with safety extension phase with crossover or continued treatment.

Condition or disease Intervention/treatment Phase
Chronic Sinusitis Chronic Rhinosinusitis (Diagnosis) Drug: LYR-210 Drug: Sham procedure control Other: Background Therapy Phase 3

Detailed Description:
This is a 52-week, multicenter, phase III, randomized, blinded, controlled, parallel group with a 24-week treatment period followed by a safety extension phase with crossover or continued treatment to evaluate the efficacy and safety of LYR-210 compared with sham control for treatment in adults with CRS.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 180 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double (Participant, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: ENLIGHTEN 1: A Phase III, Randomized, Blinded, Controlled, Parallel-Group Trial to Evaluate the Efficacy and Safety of LYR-210 for the Treatment of Chronic Rhinosinusitis (CRS) in Adults
Actual Study Start Date : January 27, 2022
Estimated Primary Completion Date : August 31, 2023
Estimated Study Completion Date : March 31, 2024

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: LYR-210
Single administration of LYR-210 drug matrix (7500 μg)
Drug: LYR-210
LYR-210 drug matrix (mometasone furoate)

Other: Background Therapy
Daily Saline Irrigation

Sham Comparator: Sham procedure control
Single mock administration procedure
Drug: Sham procedure control
Sham procedure control

Other: Background Therapy
Daily Saline Irrigation




Primary Outcome Measures :
  1. Change from baseline (CFBL) in the 7-day average composite score of 3 cardinal symptoms (3CS) in participants without nasal polyps. [ Time Frame: 24 Weeks ]
    The 3CS are nasal blockage/obstruction/congestion, anterior/posterior nasal discharge, and facial pain/pressure. Each symptom is rated on a 4-point (0-3) scale where 0=absent symptoms and 3=severe symptoms. The composite score of 3CS is the sum of the three cardinal symptom scores.


Secondary Outcome Measures :
  1. CFBL in the 7-day average CS score of nasal blockage/obstruction/congestion at Week 24 [ Time Frame: Week 24 ]
    Nasal blockage/obstruction/congestion is one of the 3 cardinal symptoms. Each symptom is rated on a 4-point (0-3) scale where 0=absent symptoms and 3=severe symptoms.

  2. CFBL in the 7-day average CS score of anterior/posterior nasal discharge at Week 24 [ Time Frame: Week 24 ]
    Anterior/posterior nasal discharge is one of the 3 cardinal symptoms. Each symptom is rated on a 4-point (0-3) scale where 0=absent symptoms and 3=severe symptoms.

  3. CFBL in the 7-day average CS score of facial pain/pressure at Week 24 [ Time Frame: Week 24 ]
    Facial pain/pressure is one of the 3 cardinal symptoms. Each symptom is rated on a 4-point (0-3) scale where 0=absent symptoms and 3=severe symptoms.

  4. CFBL in the 22-item Sino-Nasal Outcome Test (SNOT-22) total score at Week 24 [ Time Frame: Week 24 ]
    The SNOT-22 questionnaire is a 22-item disease-specific quality of life instrument. Each symptom is scored on a 6-point scale where 0 = no problem and 5 = problem as bad as it can be. The total SNOT-22 score is the sum of the 22 items and can range from 0 to 110 with higher scores indicating worse symptoms.

  5. CFBL in the 3-D volumetric CT score at Week 24 [ Time Frame: Week 24 ]
  6. Number and percent of participants requiring rescue treatment through Week 24 [ Time Frame: Week 24 ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥18
  • Diagnosed as having CRS
  • Undergone at least 2 trials of medical treatments in the past
  • Mean 3 cardinal symptom (3CS) score
  • Bilateral ethmoid disease confirmed on CT
  • Has been informed of the nature of the study and provided written informed consent
  • Agrees to comply with all study requirements

Exclusion Criteria:

  • Inability to tolerate topical anesthesia
  • Previous nasal surgery
  • Presence of nasal polyp grade 2 or higher
  • Seasonal allergic rhinitis
  • Perennial rhinitis with symptoms that are well controlled by regular use of intranasal corticosteroids
  • Severe asthma
  • History or clinical evidence or suspicion of invasive fungal sinusitis, allergic fungal rhinosinusitis, atrophic rhinitis, or odontogenic sinusitis
  • Obstruction preventing proper placement and retention of LYR-210 as seen on endoscopy
  • Anatomic variation that, in the opinion of the investigator, would adversely impact placement of LYR-210 as seen on CT
  • Known history of hypersensitivity or intolerance to corticosteroids
  • Known history of hypothalamic pituitary adrenal axial dysfunction
  • Previous pituitary or adrenal surgery
  • Dental procedure/implant on maxillary dentition within 4 weeks of the Screening visit.
  • Past or present acute or chronic intracranial or orbital complications of CRS
  • History or diagnosis (in either eye) of glaucoma or ocular hypertension
  • Past or present functional vision in only 1 eye
  • Past, present, or planned organ transplant or chemotherapy with immunosuppression
  • Currently positive for COVID-19 or residual sinonasal symptoms from a previous COVID-19 infection
  • Pregnant or breast feeding. Females of child-bearing potential must test negative for pregnancy at the time of screening
  • Evidence of disease or condition expected to compromise survival or ability to complete follow-up assessments
  • Currently participating in an investigational drug or device study
  • Determined by the investigator as not suitable to be enrolled

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT05219968


Contacts
Layout table for location contacts
Contact: Lyra Clinical 617-393-4600 lyraclinical@lyratx.com

Locations
Show Show 59 study locations
Sponsors and Collaborators
Lyra Therapeutics
Layout table for additonal information
Responsible Party: Lyra Therapeutics
ClinicalTrials.gov Identifier: NCT05219968    
Other Study ID Numbers: LYR-210-2021-004
First Posted: February 2, 2022    Key Record Dates
Last Update Posted: October 26, 2022
Last Verified: January 2022

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: Yes
Studies a U.S. FDA-regulated Device Product: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Sinusitis
Respiratory Tract Infections
Infections
Paranasal Sinus Diseases
Nose Diseases
Respiratory Tract Diseases
Otorhinolaryngologic Diseases